The price of frontier AI capability is falling towards zero. The consequence for an IP strategy is not that AI has become cheaper. It is that anything you thought you were...
The patent is rarely where the money is decided. The licence is. Three IP developments from the past week make that point, and each turns on terms settled, or left unsettled,...
If AI collapses the cost of making your product, the question is no longer how cheaply you can make it. It is what stops a competitor making the same thing. That...
There are two ways to hold a position in a technology. You can own the technology. Or you can own what it takes to build and install the technology at volume....
Adding AI to a product is not a strategy. Moving to where the value is going is. And every real move changes what your company controls, which makes it an IP...
A treatment that works once and keeps working for years is a very different commercial asset from a pill taken every day. The value is created up front. It then has...
Patent law only pays for outliers. Novelty and inventive step exist to screen out the expected, so a patent portfolio is, by design, a collection of exceptions. Hold that thought against...
Some assets cannot be built on any timeline a budget can shorten. When that is true, the choice is no longer build, buy or licence. It is licence, or stay out....
Most boards plan around a single date. The patent expires, competitors arrive, the revenue line falls off a ledge. That model is tidy, it sits in the forecast, and for high-value...
You must be logged in to post a comment.